Hussein Tawbi, Professor at The University of Texas MD Anderson Cancer Center shared a post on LinkedIn:
“Excited about the opportunity to contribute to the future direction of Society for Immunotherapy of Cancer (SITC) and help make it a leading voice in expanding access to immunotherapy. I am particularly focused on promoting inclusive clinical trial design for underrepresented populations, including those with brain metastases, autoimmune conditions, and rare tumors.
Please note that May 15th is the final day of voting for the SITC Elections.
For more information, visit the SITC website.”
Other articles about Immunotherapy on OncoDaily.